Bayer/J&J Plan Rivaroxaban Filing For Chronic Indications In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
An earlier filing for the oral factor Xa inhibitor is planned in the U.S. in 2008 for the prevention of venous thromboembolism.
You may also be interested in...
GSK’S Arixtra “Approvable” For Acute Coronary Syndromes
Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.
GSK’S Arixtra “Approvable” For Acute Coronary Syndromes
Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.
Bayer Moves Anti-Thrombotic Into Phase III For Two Indications
Bayer is set to begin Phase III trials for its antithrombotic agent BAY 59-7939 for a general venous thromboembolism indication following promising Phase II results, the company announced June 12